Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 3/20 | 0.33 |
| ▸ | RPTOR | Q8N122 | 3/20 | 0.33 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | KIF5B | P33176 | 1/20 | 0.31 |
| ▸ | ETV6 | P41212 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15031521 | 1.00 | MTOR (0.33) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL15031518 | 0.93 | MTOR (0.34) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL16229242 | 0.91 | MTOR (0.42) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL15007199 | 0.91 | MTOR (0.42) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL28915 | 0.91 | MTOR (0.42) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL30464 | 0.91 | MTOR (0.39) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL15007147 | 0.91 | MTOR (0.39) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL15031492 | 0.91 | MTOR (0.39) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL15031493 | 0.85 | MTOR (0.39) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL15007279 | 0.85 | MTOR (0.39) | MTORRPTORMLST8CHEK1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RPS6KA5, PAK5 | MTOR 1/4885RPTOR 11/4885MLST8 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.